近日，國(guó)際著名疫苗學(xué)期刊《疫苗》（Vaccine）發(fā)表了中國(guó)科學(xué)院廣州生物醫(yī)藥與健康研究院陳凌博士（客座研究員）指導(dǎo)的課題組的研究成果“Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China”,。該研究對(duì)廣州地區(qū)健康人群和艾滋病病人體內(nèi)預(yù)存5型腺病毒（Ad5）中和抗體情況進(jìn)行了流行病學(xué)調(diào)查,，證實(shí)了腺病毒載體疫苗的安全性,。
腺病毒載體疫苗具有諸多優(yōu)良的特性,，曾被認(rèn)為是疫苗研究中的希望之星，并在全球進(jìn)入大規(guī)模的二期臨床實(shí)驗(yàn),。但在2007年底,，默克公司和艾滋病疫苗試驗(yàn)聯(lián)盟（HVTN）聯(lián)合宣布，由于未能有效預(yù)防艾滋病感染,，該疫苗實(shí)驗(yàn)宣告終止,。隨后，有科學(xué)家認(rèn)為人群中預(yù)存的Ad5中和抗體是該疫苗失敗的一個(gè)原因,，但預(yù)存Ad5抗體與艾滋病易感性到底有無相關(guān)性一直還未有定論,。對(duì)此，陳凌課題組通過對(duì)廣州地區(qū)進(jìn)行了流行病學(xué)調(diào)查,，結(jié)果表明絕大多數(shù)人都有自然感染過Ad5且比例隨年齡的增長(zhǎng)而增高,。對(duì)正常人群和艾滋病感染人群之間的比較顯示其Ad5的預(yù)存中和抗體發(fā)生率并沒有統(tǒng)計(jì)學(xué)差異。這一結(jié)果及國(guó)際其它知名實(shí)驗(yàn)室的最新數(shù)據(jù)均表明：人體預(yù)存的Ad5抗體與艾滋病的易感性之間沒有相關(guān)性,，為Ad5作為疫苗載體的繼續(xù)使用提供了重要的依據(jù),。
該項(xiàng)目由國(guó)家十一五科技重大專項(xiàng)、中國(guó)科學(xué)院,、國(guó)家自然科學(xué)基金等經(jīng)費(fèi)資助,。(生物谷 Bioon.com)
doi:10.1016/j.vaccine.2011.03.042
PMC:
PMID:
Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China
Caijun Sun , Yinfeng Zhang, Liqiang Feng, Weiqi Pan, Maochao Zhang, Zheyu Hong, Xin Ma, Xiaoping Chen and Ling Chen
Recombinant adenovirus serotype 5 (Ad5) viruses have been extensively explored as vectors for vaccination or gene therapy. However, one major obstacle to their clinical application is the high prevalence of preexisting anti-Ad5 immunity resulting from natural infection. It has been reported that there are geographic variations in the prevalence of natural adenovirus infection. In the present study, we investigated the seroprevalence of Ad5 in Guangzhou, southern China by measuring the Ad5 neutralizing antibodies in blood samples collected from several sites. The seroprevalence was 77.34% in the general healthy population. The seroprevalence and antibody titers increased with age, with the older population (41-72 years old) having the highest seropositivity (84.8%) and percentage (54.4%) of high Ad5 neutralizing antibody titers (>1000). The dynamics of Ad5 neutralizing antibodies were stable and persistent over the course of eight months. Furthermore, the seroprevalence of Ad5 in the HIV-infected AIDS patients was investigated and there was no significant difference from the general healthy population. Our survey provides useful insights for the future development of Ad5-based vaccination and gene therapy.
